CellFE

CellFE develops a microfluidic-based intracellular gene delivery platform that enables efficient delivery of gene-editing molecules into human cells for cell therapy manufacturing. The company's Ryva mechanoporation system uses a benchtop device for research and process development, achieving greater than 90% cell viability while delivering payloads of 10+ kilobases into any cell type. The technology is viral vector-free, scalable from 1 million to billions of cells, and reduces manufacturing processes to 1-2 days including complex editing. This elegant approach surpasses current industry standards by maintaining superior cell health and functionality while enabling rapid, complex genome editing. The platform supports cell therapy innovators in scaling seamlessly from research to clinical to commercial manufacturing, addressing critical challenges including long vein-to-vein times, scalability limitations, and high manufacturing costs that restrict patient access to lifesaving cell therapies. Founded in 2018 and headquartered in Berkeley, United States, the company has raised approximately $26.8M in Series A funding from investors including Cota Capital, Khosla Ventures, GreatPoint Ventures, M Ventures, and Dynamk Capital.